BRAF and plasma cell myeloma: Mutations in BRAF, NRAS, and KRAS components of the MAPK/ERK signaling pathway are frequently identified in melanoma, colorectal, multiple myeloma (MM), papillary thyroid, lung, and ovarian cancers [25,26,27,28,29,30].